EUVIMEDEUVIMED entdecken
Crossref

Patterns of recurrence in surgically treated women for TP53-mutated endometrial carcinomas

Flore-Anne Pain, Guillaume Beinse, Henri Azaïs, Marie Auvray-Kuentz, Louis-Marie Garcin, Nicolas Delanoy, Enrica Bentivegna, Louise Benoit, Huyen-Thu Nguyen-Xuan, Hélène Blons, Emmanuelle Fabiano, Marie-Aude LE Frère Belda und 2 weitere

European Journal of Surgical Oncology · 2023

DOI: 10.1016/j.ejso.2023.06.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2023. Verfasst von Flore-Anne Pain und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic and Breast Oncologic Surgery, Georges Pompidou European Hospital, APHP. Centre, Paris, France; Université Paris Cité, Franc…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Peritoneal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To describe the patterns of recurrence and the prognosis of patients with a recurrent TP53 mutated endometrial carcinoma treated initially by surgery. METHODS: All patients with endometrial carcinoma, treated at hospital European Georges Pompidou between 2001 and 2021 were retrospectively included. Patients were separated into two groups: TP53-mutated and not TP53-mutated (POLE/ultramutated-like (POLEmut), dMMR (mismatch repair-deficient) and NSMP (No specific molecular profile)). We estimated survival using recurrence free survival, overall survival and overall survival from recurrence. The risk of recurrence according to TP53 status and the type of recurrence (locoregional recurrence, peritoneal recurrence, and metastasis) were also compared between the two groups. RESULTS: Two hundred and ninety-one patients with endometrial carcinoma were included. Of these, 57 were TP53-mutated and 234 patients were not TP53-mutated. TP53 mutated patients had the worst recurrence free survival and overall survival (p < 0.001 for each). The hazard rate of recurrence was higher during the first three years for TP53 mutated endometrial carcinoma then tend to join the one of no TP53 mutated. There was a statistical difference between the two groups in terms of cumulative incidence of peritoneal recurrence (p = 0.002). There was, however, no statistical difference in overall survival from recurrence. CONCLUSIONS: TP53-mutated endometrial carcinoma were more likely to experience a recurrence during the first three years and most often peritoneal recurrence compared to not TP53-mutated. TP53 status in endometrial carcinoma could be useful to define follow-up. Further prospective studies are required to assess the predictive impact of TP53 mutation on chemotherapy benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsPeritoneal NeoplasmsFemaleHumansMutationNeoplasm Recurrence, LocalPrognosisRetrospective StudiesTumor Suppressor Protein p53

Stichwörter der Autor:innen

Endometrial cancerLocal recurrenceRecurrenceSurvivalTP53-Mutation

Substanzen

TP53 protein, humanTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Department of Gynecologic and Breast Oncologic Surgery, Georges Pompidou European Hospital, APHP. Centre, Paris, France; Université Paris Cité, France. Electronic address: flore.anne.pain@gmail.com.
  • Université Paris Cité, France; Institut du Cancer Paris CARPEM, F-75006, Paris, France; Centre de Recherche des Cordeliers, « Equipe labélisée Ligue Contre le Cancer » Sorbonne Université, Université de Paris, INSERM UM…
  • Department of Gynecologic and Breast Oncologic Surgery, Georges Pompidou European Hospital, APHP. Centre, Paris, France; Université Paris Cité, France; Institut du Cancer Paris CARPEM, F-75006, Paris, France; Centre de…
  • Université Paris Cité, France; Department of Medical Oncology, Georges Pompidou European Hospital, APHP. Centre, Paris, France.
  • Department of Gynecologic and Breast Oncologic Surgery, Georges Pompidou European Hospital, APHP. Centre, Paris, France; Institut du Cancer Paris CARPEM, F-75006, Paris, France.
  • Department of Gynecologic and Breast Oncologic Surgery, Georges Pompidou European Hospital, APHP. Centre, Paris, France; Environmental Toxicity, Therapeutic Targets, Cellular Signaling and Biomarkers, T3S, INSERM UMR-S…

Zitieren

APA

Pain, F. A., Beinse, G., Azaïs, H., Auvray-Kuentz, M., Garcin, L. M., Delanoy, N., Bentivegna, E., Benoit, L., Nguyen-Xuan, H. T., Blons, H., Fabiano, E., LE Frère Belda, M. A., Bats, A. S., & Koual, M. (2023). Patterns of recurrence in surgically treated women for TP53-mutated endometrial carcinomas. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2023.06.006

Vancouver

Pain FA, Beinse G, Azaïs H, Auvray-Kuentz M, Garcin LM, Delanoy N, et al. Patterns of recurrence in surgically treated women for TP53-mutated endometrial carcinomas. European Journal of Surgical Oncology. 2023. doi:10.1016/j.ejso.2023.06.006

BibTeX
@article{Pain2023,
  author = {Pain, Flore-Anne and Beinse, Guillaume and Azaïs, Henri and Auvray-Kuentz, Marie and Garcin, Louis-Marie and Delanoy, Nicolas and Bentivegna, Enrica and Benoit, Louise and Nguyen-Xuan, Huyen-Thu and Blons, Hélène and Fabiano, Emmanuelle and LE Frère Belda, Marie-Aude and Bats, Anne-Sophie and Koual, Meriem},
  title = {Patterns of recurrence in surgically treated women for TP53-mutated endometrial carcinomas},
  journal = {European Journal of Surgical Oncology},
  year = {2023},
  doi = {10.1016/j.ejso.2023.06.006}
}
Kostenlos starten →